Ad
related to: rifaximin 550 for hepatic encephalopathy
Search results
Results from the WOW.Com Content Network
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like ...
Salix Pharmaceuticals Previews American College of Gastroenterology 2012 RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NAS: SLXP) today announced that educational activities and ...
Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. [2] Its onset may be gradual or sudden. [ 2 ] Other symptoms may include movement problems, changes in mood , or changes in personality . [ 2 ]
Salix Pharmaceuticals Reports 1Q2013 Results 1Q Results Meet and/or Exceed Management Guidance 18% Increase in Year-over-Year 1Q Product Revenue 26% Increase in Year-over-Year 1Q XIFAXAN ® 550 mg ...
Rifaximin is an oral rifamycin marketed in the US by Salix Pharmaceuticals that is poorly absorbed from the intestine. It has been used to treat hepatic encephalopathy and traveler's diarrhea . [ 19 ]
For premium support please call: 800-290-4726 more ways to reach us
Salix Pharmaceuticals Acquires Worldwide Rights to Olon's Intellectual Property Relating to Amorphous Rifaximin RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NAS: SLXP) today ...
One scheme defines "acute hepatic failure" as the development of encephalopathy within 26 weeks of the onset of any hepatic symptoms. This is sub-divided into "fulminant hepatic failure", which requires onset of encephalopathy within 8 weeks, and "subfulminant", which describes onset of encephalopathy after 8 weeks but before 26 weeks. [ 6 ]
Ad
related to: rifaximin 550 for hepatic encephalopathy